Table 2 Clinical CAR trials targeting T cell malignancies
From: Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
| T cell antigen | Clinical Trials | Sponsor | CAR costimulatory domain | Additional intervention | Phase | Status | Ref |
|---|---|---|---|---|---|---|---|
| CD5 | NCT03081910 (MAGENTA) | Baylor College of Medicine | CD28 | None | Phase I | Recruiting | |
| CD7 | NCT04004637 | PersonGen BioTherapeutics | Phase I | Recruiting | |||
| NCT04033302 | Shenzhen Geno-Immune Medical Institute | Phase I/II | Recruiting | ||||
| NCT03690011 | Baylor College of Medicine | CD28 |
CRISPR/Cas9 CD7-editing | Phase I | Not yet recruiting | ||
| NCT02742727 | PersonGen BioTherapeutics | CD28 and 4-1BB | NK-92 cells | Phase I/II | Unknown | ||
| CD4 | NCT03829540 | Stony Brook University | CD28 and 4-1BB | Phase I | Recruiting | ||
| CD30 | NCT01192464 | Baylor College of Medicine | EBV-specific CTL | Phase I | Active, not recruiting | ||
| NCT03383965 | Immune Cell Inc | 2nd generation | Phase I | Recruiting | |||
| NCT02690545 | UNC Lineberger Comprehensive Cancer Center | Phase I/II | Recruiting | [62] | |||
| NCT02259556 | Chinese PLA General Hospital | 4-1BB | Phase I/II | Recruiting | [63] | ||
| NCT02958410 | Southwest Hospital, China | Phase I/II | Recruiting | ||||
| NCT03049449 | NCI | Phase I | Recruiting | ||||
| NCT01316146 | UNC Lineberger Comprehensive Cancer Center | CD28 | Phase I | Active, not recruiting | [55] | ||
| NCT02917083 (RELY-30) | Baylor College of Medicine | CD28 | Phase I | Recruiting | [64] | ||
| NCT04008394 | Wuhan Union Hospital, China | 3rd generation | Phase I | Recruiting | |||
| NCT03602157 | UNC Lineberger Comprehensive Cancer Center | CCR4 overexpression | Phase I | Recruiting | |||
| NCT02663297 | UNC Lineberger Comprehensive Cancer Center | CD28 | Phase I | Recruiting | |||
| TRBC1 | NCT03590574 | Autolus Limited | RQR8 safety mechanism | Phase I/II | Recruiting |